Home/Filings/4/0001628280-24-052104
4//SEC Filing

Mathew Aby J. 4

Accession 0001628280-24-052104

CIK 0000834365other

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 5:19 PM ET

Size

7.4 KB

Accession

0001628280-24-052104

Insider Transaction Report

Form 4
Period: 2024-12-16
Mathew Aby J.
EVP & Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2024-12-16$27.33/sh7,604$207,817276,315 total
  • Sale

    Common Stock

    2024-12-17$27.16/sh13,196$358,403263,119 total
Footnotes (3)
  • [F1]The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 6-14-2024.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.88 to $28.33, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.62 to $27.48, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Issuer

BIOLIFE SOLUTIONS INC

CIK 0000834365

Entity typeother

Related Parties

1
  • filerCIK 0001556355

Filing Metadata

Form type
4
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 5:19 PM ET
Size
7.4 KB